Preferred Label : apremilast;

MeSH note : a PDE4 inhibitor;

CISMeF synonym : CC 10004;

MeSH hyponym : CC10004; CC-10004;

Is substance : O;

UNII : UP7QBP99PN;

InChIKey : IMOZEMNVLZVGJZ-QGZVFWFLSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3598324/fr/otezla-apremilast-psoriasis-en-plaques-modere-a-severe-chez-les-enfants-et-adolescents-a-partir-de-6-ans
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
apremilast
administration, oral
evaluation of the transparency committee
child
psoriasis
apremilast
adolescent

---
https://www.ema.europa.eu/en/medicines/human/EPAR/apremilast-accord
2024
false
false
false
Netherlands
French
English
drug approval
europe
apremilast
apremilast
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drugs, generic

---
https://www.rheuma-net.ch/fr/doc/apremilast-f/viewdocument/354
2024
Switzerland
guideline
Background Treatment
apremilast
apremilast
Apremilast, (+/-)-
Apremilast

---
https://www.has-sante.fr/jcms/p_3242941/fr/otezla
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
apremilast
adult
Behcet syndrome
Behçet's disease affecting oral mucosa (disorder)
oral ulcer
anti-inflammatory agents, non-steroidal
buccal ulcerations due to Behçet's disease
evaluation of the transparency committee
apremilast
thalidomide

---
https://www.ema.europa.eu/medicines/human/EPAR/Otezla
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
apremilast
apremilast
apremilast
drug approval
europe
adult
psoriasis
arthritis, psoriatic
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
administration, oral
anti-inflammatory agents, non-steroidal
anti-inflammatory agents, non-steroidal
risk management
drug monitoring
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
clinical trials as topic
drug evaluation, preclinical
thalidomide
thalidomide
thalidomide

---
Summary Basis of Decision (SBD) for Otezla
Apremilast, 10 mg, 20 mg, and 30 mg, tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00238
2015
false
false
false
Canada
French
English
drug approval
canada
apremilast
apremilast
summary of product characteristics
administration, oral
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
adult
psoriasis
aged
pregnancy
breast feeding
drug evaluation
risk assessment
treatment outcome
anti-inflammatory agents, non-steroidal
anti-inflammatory agents, non-steroidal
antipsoriatics for systemic use
drug evaluation
thalidomide
thalidomide
thalidomide

---
http://www.has-sante.fr/portail/jcms/c_2585408/fr/otezla
http://www.has-sante.fr/portail/jcms/c_2585408/fr/otezla-apremilast-immunosuppresseur-inhibiteur-de-pde4
2015
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
apremilast
apremilast
apremilast
adult
arthritis, psoriatic
psoriasis
treatment outcome
insurance, health, reimbursement
aged
guidelines for drug use
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
thalidomide
thalidomide
thalidomide

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.